




MONASH
University

**AUSTRALIAN
AND
NEW ZEALAND
MYELOMA
AND RELATED
DISEASES
REGISTRY
(ANZ MRDR)**

2025 ANNUAL REPORT



The MRDR is a clinical registry established in 2012 that aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

The registry has participating hospitals and clinics in all jurisdictions in Australia and New Zealand. Data collected includes patient demographics, clinical characteristics, test results at diagnosis, treatment, response, follow-up and outcomes including survival and quality of life.

BENCHMARKING TO IMPROVE CARE

The MRDR provides six-monthly data reports to participating sites comparing each site's registry data to the rest of the MRDR cohort in their country. Treatment varies between centres, and these reports allow treating institutes and clinicians to identify areas of difference where there may be opportunities for improvement. In this way the MRDR facilitates work towards higher quality care.

MRDR NETWORK

The established MRDR network and data collection infrastructure of >60 participating metropolitan & regional, public & private health services throughout Australia and New Zealand provides a solid base from which to conduct many and diverse projects, and enhances our capacity for rapid translation of results. In addition, the MRDR's close association with relevant professional and research groups, Myeloma Australia (a national patient advocacy group), policy-makers and industry partners, further strengthens our capacity for research translation.

The MRDR informs national and international policy, guidelines and practice through representation of Management and Steering committee members in professional groups, as well as partner involvement:



- Haematology Society of ANZ (HSANZ)
- Haematology Society of ANZ Nursing Group (HSANZ NG)
- Myeloma Special Practice Network (M-SPN) of the HSNZ NG
- Cancer Nurses Society of Australia (CNSA)
- Myeloma Australia
- Myeloma Australia Medical Scientific Advisory Group (MSAG)
- International Myeloma Working Group (IMWG)
- Myeloma Research Group, Monash University (MRG)
- Australasian Leukaemia & Lymphoma Group (ALLG)
- Australasian Myeloma Research Consortium (AMaRC)
- Centre for Health Economics, Monash University (CHE)
- Synergistic relationship with pharmaceutical industry partners

MRDR 2025 AT A GLANCE



8978 PATIENTS REGISTERED


1051 NEW PATIENTS

- 72% MULTIPLE MYELOMA (MM)
- 15% MGUS¹
- 9% SMOULDERING MM¹ (SMM)
- 4% PCL² / PLASMACYTOMA / AL AMYLOIDOSIS




M1000 BIOBANK PATIENTS:
THE ONLY PROSPECTIVE FULLY ANNOTATED 'LIQUID BIOPSY' BIOBANK IN THE WORLD



795 M1000 BIOBANK PATIENTS:



16 MYELOMA 1000 APPROVED SITES




45 REQUESTS:
DATA / ANALYSES / REPORTS



65 HOSPITALS & CLINICS

61 APPROVED³
4 PENDING APPROVAL



MULTIPLE MYELOMA

PATIENTS
AGE (MEDIAN): 68 YEARS
FEMALE 39% / MALE 61%

SURVIVAL
63% OF PATIENTS SURVIVE TO 5 YEARS

STEM CELL TRANSPLANTS IN PATIENTS WITH THE FOLLOWING AGE AT DIAGNOSIS:⁴

- >70 YEARS: 9%
- <70 YEARS: 75%
- 65-70 YEARS: 62%
- <65 YEARS: 81%

1. Possible precursor disease for MM
2. PCL = Plasma cell leukemia
3. Ethics approval and local governance authorisation obtained
4. Patients at least 1 year post-diagnosis with some post-registration follow-up.

MRDR RESEARCH HIGHLIGHTS FOR 2025

EpiMAP Myeloma: Epidemiological modelling to deliver better care for Australian patients with myeloma

Project Funding:

Medical Research Future Fund (MRFF) – Targeted Health System and Community Organisation Research

Chief investigators:

Zoe McQuilten, Dennis Petrie, Andrew Spencer, Erica Wood, Anthony Harris, Laura Fanning

The EpiMAP Myeloma discrete-event simulation model continued to be used for economic evaluations of MM therapies in Australia. In 2025, we published a post-market economic evaluation of bortezomib, lenalidomide and dexamethasone (VRd) versus pre-funding standard of care for newly diagnosed MM in PharmacoEconomics, demonstrating the utility of registry-based modelling for assessing the real-world cost effectiveness of funded therapies. We also submitted a pre-market economic evaluation to the PBAC Drug Utilisation Sub-Committee ahead of a funding decision, illustrating the model's capacity to inform prospective policy decisions when real-world data on novel treatments are not yet available.

The model uses real-world data from the MRDR to determine disease trajectories and treatment outcomes at the individual patient level, and is available to inform health-care policy and service delivery planning, including decision-making for future funding of high-cost MM therapies.



ZEPFHR MM trial: A Centralized Platform for Functional High Risk Multiple Myeloma

Project Funding:

MRFF – Clinical Trials Activity

Chief investigators:

Andrew Spencer, P Joy Ho, Hang Quach, Geoffrey Hill, Roger Reddel, Nicholas Bingham, John Reynolds, Sridurga Mithraprabhu, Wee Joo Chng, Wendy Erber, Sueh-Li Lim, Christian Bryant.

Approximately 20% of MM patients in the ANZ MRDR develop relapsed MM within 12 months of diagnosis. These functional high-risk (FHR) MM patients do not respond well to currently available treatments and have a median overall survival of <20 months. Circulating tumour DNA sequencing by the research team has provided important insights into the driver mutations associated with this FHR disease.

The ZEPFHR-MM project is a platform trial to evaluate novel therapies for FHR MM and conduct studies to better understand its biology. The platform leverages the MRDR and AMaRC trial network and incorporates a novel adaptive statistical design allowing early assessment of treatment response to determine futility or identify treatments of interest, while enabling new treatment combinations to be introduced efficiently within the trial. The project also involves the recently established AMaRC Correlatives Network, including international collaborations with National University of Singapore and Fred Hutchinson Cancer Center. The first domain, utilising teclistamab and talquetamab, is nearly fully recruited. The results of a preliminary analysis were submitted for EHA 2026. Subsequent domains are currently in-development and expected to be opened in the second half of 2026 onwards.



MY-PROMPT-2: More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures

Project Funding:

MRFF – Rare Cancers, Rare Diseases and Unmet Needs

Chief investigators:

Andrew Spencer, Claudia Rutherford, John Reynolds, P Joy Ho, Zoe McQuilten, Elizabeth Moore, Tracy King, Erica Wood, Simon Harrison, Adam Irving.

The MY-PROMPT-2 trial will test whether real-time symptom feedback to clinicians improves duration on therapy in patients with relapsed MM receiving standard care. MM treatment is complex and costly, however survival benefits seen in clinical trials are often not reflected in clinical practice, partly because many patients stop therapy early due to side-effects, reducing the survival benefit of optimal therapy duration. If clinicians are aware of emerging symptoms, leading to timely intervention, duration on therapy could be optimised, resulting in more efficient use of these high-cost therapies, and better patient outcomes. The trial is open for recruitment at approved, activated sites and new sites are welcome.



The MRDR encourages and supports researchers in developing and pursuing their question of interest.

FRAIL-M: Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma

Project Funding:

MRFF – Low Survival Cancers and Diseases

Chief investigators:

Andrew Spencer, Zoe McQuilten, Hang Quach, Peter Mollee, Erica Wood, John Reynolds, Ruth Hubbard, Richard De Abreu Lourenco.

The FRAIL-M trial evaluates which competing treatment options are most appropriate for transplant-ineligible myeloma patients according to frailty status. Adapting standard treatment regimens based on frailty assessment in this patient group is recommended in Australian guidelines; however, this approach has not been tested in a clinical trial, nor have the two most common frontline treatment strategies been directly compared. Findings from this study will address these evidence gaps and provide a robust framework for optimisation of treatment in transplant-ineligible myeloma patients.

The trial will also inform more cost-effective use of publicly funded high-cost frontline anti-myeloma therapies such as bortezomib and lenalidomide. FRAIL-M recruited patients across Australia and New Zealand through the AMaRC clinical trials network and, in 2025, recruitment closed following successful enrolment. Ongoing follow-up and planned analyses will provide evidence on frailty-adapted treatment strategies in transplant-ineligible myeloma in real-world ANZ settings.



MRDR COLLABORATIONS



apacmrd.org

Asia-Pacific (APAC) MRDR

The APAC MRDR is a sister registry to the MRDR in the Asia-Pacific region, and collects the same data to facilitate comparisons between countries.

Participation has grown to 30 hospitals across Korea, Malaysia, Singapore, Taiwan and China and more than 3,500 patients have been enrolled so far. As the dataset continues to mature, the registry is participating in an increasing number of collaborative research initiatives, including analyses with the ANZ MRDR and international partners.



amaronline.org

AMaRC: The Australasian Myeloma Research Consortium

AMaRC is a not-for-profit myeloma clinical trial research group composed of clinicians and scientists who develop and conduct investigator-led early phase and proof-of-concept studies, trialling novel drug and biologic products in Australia and New Zealand. AMaRC has valued partnerships with the pharmaceutical industry, the Myeloma Research Group laboratory, the Australasian Leukaemia & Lymphoma Group (ALLG), and Myeloma Australia. In some studies, AMaRC leverages the MRDR's established infrastructure and national site network as a platform for MM trials.

Recently, the AMaRC Myeloma Correlatives Network was established as an international alliance of correlative science research centres with expertise across multiple analytical platforms, including genomics, transcriptomics, metabolomics, proteomics and immune profiling. In 2025, AMaRC expanded investigator-led trial activity, opening the ZEPFHR-MM platform trial for functional high-risk MM and the Dara@home trial assessing feasibility of daratumumab self-administration. The BelaCarD study of belantamab mafodotin also expanded with a second cohort using a less intensive dosing regimen to improve deliverability while maintaining efficacy. In addition, IBIS study results (iberdomide and isatuximab in FHR MM) were presented at AACR and ASH 2025, highlighting early disease control and promising efficacy in FHR MM.



myeloma.org.au

Myeloma Australia

Myeloma Australia (MA) is the only myeloma-specific patient advocacy group in Australia. They support, educate, inform, and empower people living with MM, and their loved ones. Myeloma Australia is advocating for significant improvements in the availability of MM treatments in Australia and is driving the scientific conversation towards cure. The MRDR and MA work closely together, including through representation on the MRDR Steering Committee, support of and strong MRDR presence at the National Myeloma Workshop hosted by MA, funding support, and collaboration on grant applications and research projects. Numerous MRDR Steering Committee members and Principal Investigators form part of MA's Medical and Scientific Advisory Group – the peak body convened to collaborate and facilitate advances and medical care for MM in Australia.

ANZ & APAC MRDR: COMBINED DATA SNAPSHOT

Analyses using combined ANZ and APAC MRDR data have been completed for several data requests (see 'Presentations' on page 10) showing regional variation and the potential for this collaboration. In Tables 2 and 3 we provide a snapshot of the combined MRDR data by location from 1 January 2018 to January 2026.

Table 1. Current site accrual

	TOTAL	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN	CHINA
ACTIVE HOSPITALS	88	48	10	13	3	10	2	2

Table 2. Age in years at diagnosis and gender for patients with multiple myeloma (MM)

	TOTAL	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN	CHINA
N	9656	4917	1396	1422	256	261	43	896
AGE, MEDIAN (IQR)^	67 (60, 75)	68 (60, 76)	70 (61, 77)	65 (58, 72)	67 (60, 73)	64 (56, 71)	66 (57, 72)	65 (58, 72)
AGE >70 YEARS^	41%	43%	48%	30%	38%	27%	31%	33%
GENDER (MALE)	60%	61%	59%	56%	56%	56%	62%	57%

Table 3. Most common MM chemotherapy regimens and patients who received an ASCT

	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN	CHINA
MOST COMMON 1L	VRd (60%)	VCd 70%)	VRd (30%)	VRd (35%)	VTd (40%)	VRd (39%)	VRd (40%)
MOST COMMON 1L, NO ASCT	VRd (61%)	VCd (78%)	Rd (32%)	VRd (29%)	VCd (36%)	VRd (77%)	VRd (30%)
MOST COMMON 2L	DVd (55%)	Rd (18%)	KRd (26%)	VRd (13%)	VRd; Rd (27%)	VTd; VRd (20%)	DVd (11%)
RECEIVED ASCT*	48%	36%	60%	48%	38%	33%	41%
- AGE <70 YEARS receiving ASCT*^	76%	64%	82%	69%	50%	60%	57%
- AGE >70 YEARS receiving ASCT*^	9%	3%	1%	7%	0%	0%	4%

1L: first-line therapy, 2L: second-line therapy, ASCT: Autologous stem cell transplant.

* Only patients with at least 1-year post-diagnosis and with some follow-up data post-registration were included.

^ Age: at Diagnosis; for Singapore, Date of Birth unknown – age estimated using 01 July "Year of Birth". N/A: not available/insufficient data.

Chemotherapy Codes

CODE	CHEMOTHERAPY REGIMEN
DVd	daratumumab, bortezomib, dexamethasone
KRd	carfilzomib, lenalidomide, dexamethasone
Rd	lenalidomide, dexamethasone
VCd	bortezomib, cyclophosphamide, dexamethasone
VRd	bortezomib, lenalidomide, dexamethasone
VTd	bortezomib, thalidomide, dexamethasone

MRDR PEER-REVIEWED PUBLICATIONS TO DATE

New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)

Li J, Melsew Y, Wellard C, Moore EM, Ho PJ, wQuach H, Harrison SJ, Rajagopal R, Augustson B, Wood EM, Spencer A. Clin Lymphoma Myeloma Leuk. 2025 Oct 20:S2152-2650(25)04249-1. doi: 10.1016/j.clml.2025.10.013.

No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

Lim SL, Wellard C, Rajagopal R, Harrison SJ, Khot A, Quach H, Ho PJ, Moore E, Wood E, Spencer A. Br J Haematol. 2025 Nov 8. doi: 10.1111/bjh.70238.

A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data

Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. Pharmacoeconomics. 2025 Oct 29. doi: 10.1007/s40273-025-01554-4.

Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry

Zhao, S., Wellard, C., Moore, E., Spencer, A., Quach, H., Ho, J.P., McDonald, E.J., Mollee, P., Harrison, S.J., Augustson, B., Wood, E.M., McQuilten, Z.K., Rajagopal, R. Clin Lymphoma Myeloma Leuk. 2025 Aug 9:S2152-2650(25)00269-1. doi: 10.1016/2025.08.004./j.clml.

Presence of 1q21 gain and amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients

Lim, K. J. C., Wellard, C., Moore, E., Ninkovic, S., Chng, W. J., Spencer, A., Mollee, P., Hocking, J., Ho, P. J., Janowski, W., Kim, K., McCaughan, G., Dun, K., McQuilten, Z. K., Chen, F., & Quach, H. Clin Lymphoma Myeloma Leuk. 2025 Apr;25(4):243-248. doi: 10.1016/j.clml.2024.11.002.

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812

The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)

Ho PJ, Moore E, Wellard C, Quach H, Blacklock H, Harrison SJ, MacDonald EJ, McQuilten ZK, Wood EM, Mollee P, Spencer A. Br J Haematol. 2024 Jul 4. doi: 10.1111/bjh.19624

Variation in immunoglobulin use and impact on survival in myeloma

Chai, KL, Wellard C, LeTP T, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim KH, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso ACY, Wong KSQ, Yoon SS, Spencer A, Wood EM, McQuilten ZK. EJHaem. 2024 May;1-8 doi: 10.1002/jha2.938

Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry

Lim SL, Wellard C, Moore E, Harrison SJ, Hang Q, Ho J, Rajagopal R, Spencer A. Intern Med J. 2023 Dec 27. doi: 10.1111/imj.16277

The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)

Lim KJ, Wellard C, Talaulikar D, Tan JL, Loh J, Puvanakumar P, Kuzich JA, Ho M, Murphy M, Zeglins N, Low MS, Routledge D, Lim AB, Gibbs, SD, Quach H, Morgan S, Moore E and Ninkovic S. EJHaem. 2023 Jul;4(3): e639-e646. doi:10.1002/jha2.742

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Joanne Tan, Cameron Wellard, Elizabeth Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon Harrison, Emma-Jane McDonald, P Joy Ho,

Miles Prince, Bradley Augustson, Philip Campbell, Zoe McQuilten, Erica Wood, Andrew Spencer; Myeloma and Related Diseases Registry Investigators. Br J Haematol. 2023 Jan;200(2):e17-e21. https://doi.org/10.1111/bjh.18536

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Zoe McQuilten, Cameron Wellard, Elizabeth Moore, Bradley Augustson, Krystal Bergin, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer; Australian and New Zealand Myeloma and Related Diseases Registry. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/bjh.18324

Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Elizabeth Moore, Hilary Blacklock, Cameron Wellard, Ruth Spearing, Luke Merriman, Sarah Poplar, Anup George, Bart Baker, Henry Chan, Zoe McQuilten, Erica Wood, Andrew Spencer on behalf of the MRDR investigators. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8): e762-e769. doi: 10.1016/j.clml.2022.04.004

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.

Stephen Boyle, Cameron Wellard, Elizabeth Moore, Hilary Blacklock, Simon Harrison, P Joy Ho, Jay Hocking, Zoe McQuilten, Hang Quach, Ruth Spearing, Erica Wood, Andrew Spencer, Peter Mollee, Myeloma and Related Diseases Registry investigators. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ejh.13677u

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).

Krystal Bergin, Cameron Wellard, Bradley Augustson, Rachel Cooke, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Elizabeth Moore, Zoe McQuilten, Erica Wood, Andrew Spencer, Australian and New Zealand Myeloma and Related Diseases Registry investigators. Bone Marrow Transplant. 2021 Oct;56(10):2533-2543. doi: 10.1038/s41409-021-01308-8

The myeloma landscape in Australia and New Zealand: the first eight years of the Myeloma and Related Diseases Registry (MRDR).

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Bradley Augustson, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer, Australian and New Zealand Myeloma and Related Diseases Registry investigators. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e510-e520. doi: 10.1016/j.clml.2021.01.01

Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial.

Elizabeth Moore, Tracy King, Erica Wood, Rasa Ruseckaite, Daniela Klarica, Andrew Spencer, P Joy Ho, Hang Quach, Miles Prince, Zoe McQuilten. Am J Hematol. 2020 Jul;95(7):E178-E181. doi: 10.1002/ajh.25815

Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry.

P Joy Ho, Elizabeth Moore, Zoe McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010

Myeloma in the Real World: what is really happening?

Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.e1. doi: 10.1016/j.clml.2016.12.002

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.

Krystal Bergin, Elizabeth Moore, Zoe McQuilten, Erica Wood, Bradley Augustson, Hilary Blacklock, P Joy Ho, Noemi Horvath, Tracy King, John McNeil, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Andrew Spencer. BMC Med Res Methodol. 2016 Nov 9;16(1):151. doi: 10.1186/s12874-016-0250-z

MRDR PRESENTATIONS 2025

American Society of Haematology (ASH) Annual Meeting December 2025, Florida

Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real-world evidence of adverse outcomes for high-risk groups (Poster)

Ghassan Zammar, Bradley Augustson, Elizabeth Moore, Cameron Wellard, Elham Ashrafi, Hasib Sidiqi, Kenneth J C Lim, Dejan Radeski, Alannah Jackson, Krystal Bergin, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Rajeev Rajagopal, Brian Rosengarten, Erica Wood, Zoe McQuilten and Andrew Spencer, on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry investigators

Blood October 2025, Perth MRDR Annual Breakfast Meeting (hybrid)

Real world myeloma in Australia and New Zealand & Asia-Pacific: Registry progress and latest data
A Spencer et al.

Presentations

Regional trends in first-line myeloma treatment: Real world results from the Australian & New Zealand and Asia-Pacific Myeloma and Related Diseases Registries (Oral)

Naomi Aoki, Elizabeth Moore, Cameron Wellard, Elham Ashrafi, Tracy Zhang, Chang Ki Min, Jeffrey Huang, Kihyun Kim, Wee Joo Chng, Gin Gin Gan, Sung-hoon Jung, Ji Hyun Lee, Peter Mollee, Tracy King, Simon Harrison, Rajeev Rajagopal, P Joy Ho, Krystal Bergin, Zoe McQuilten, Erica Wood, Andrew Spencer

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence of Clinical Features and Adverse Outcomes for High Risk Groups (Oral)

Ghassan Zammar, Bradley Augustson, Elizabeth Moore, Cameron Wellard, Elham Ashrafi, Hasib Sidiqi, Kenneth J C Lim, Dejan Radeski, Alannah Jackson, Krystal Bergin, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Rajeev Rajagopal, Brian Rosengarten, Erica Wood, Zoe McQuilten and Andrew Spencer, on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry

Comparing Australia and New Zealand Patients with Multiple Myeloma: Clinical Characteristics, Treatment and Survival – a Retrospective Study from MRDR (Oral)

Jian Li, Yayehirad Melsew, Cameron Wellard, Elizabeth Moore, P Joy Ho, Hang Quach, Simon Harrison, Rajeev Rajagopal, Bradley Augustson, Erica Wood, Andrew Spencer on behalf of the MRDR Investigators

Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant-ineligible patients receiving first-line VRd, Rd and VCd: Results from the ANZ MRDR (Oral)

Sarah Zhao, Cameron Wellard, Elizabeth Moore, Andrew Spencer, Hang Quach, P. Joy Ho, Emma-Jane McDonald, Peter Mollee, Simon J Harrison, Bradley Augustson, Erica Wood, Zoe McQuilten, Rajeev Rajagopal on behalf of the ANZ MRDR investigators

Bortezomib, lenalidomide and dexamethasone versus standard of care for newly diagnosed multiple myeloma: A post-market economic evaluation using registry data (Poster)

Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, Andrew Spencer, Zoe K McQuilten

Outcomes of patients with multiple myeloma post-BCMA directed treatment: an Australian perspective (Poster)

Jessica Ling, Elizabeth Moore, Cameron Wellard, Andrew Spencer, P. Joy Ho, Peter Mollee, Simon J. Harrison, Bradley Augustson, Hang Quach, M. Hasib Sidiqi

International Myeloma Society (IMS) Annual Meeting September 2025, Toronto

Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR) (Poster)

Melissa Ng Liet Hing, Cameron Wellard, Diva Baggio, Elizabeth Moore, Emma-Jane Furphy, Hayley Beer, Erica Wood, Zoe McQuilten, P Joy Ho, Hang Quach, Peter Mollee, Bradley Augustson, Rajeev Rajagopal, Simon Harrison, Andrew Spencer, Amit Khot

Outcomes of patients with multiple myeloma post-BCMA directed treatment: an Australian perspective (Poster)

Jessica Ling, Elizabeth Moore, Cameron Wellard, Andrew Spencer, P. Joy Ho, Peter Mollee, Simon J. Harrison, Bradley Augustson, Hang Quach, M. Hasib Sidiqi

European Haematology Association (EHA) Annual Meeting June 2025, Milan

Evaluating the impact of ethnicity on the outcome of multiple myeloma in Australia and New Zealand: Data from the Myeloma and Related Diseases Registry (Poster)

Silvia Ling, Yayehirad Melsew, Cameron Wellard, Anne-Marie Marivel, Adam Bryant, Elizabeth Moore, Erica Wood, Zoe McQuilten, Andrew Spencer

New Zealand Multiple Myeloma Group Biannual Meeting May 2025, New Zealand

Myeloma and Related Diseases Registry: Updates from a NZ perspective (Oral)

Rajeev Rajagopal

Heidelberg Multiple Myeloma Workshop April 2025, Heidelberg

Disparities in Health Care Systems - First-line therapy in South Korea (Oral)

Jihyun Lee


PARTICIPATION & ENGAGEMENT

The MRDR supports site research staff who enter data, as well as researchers throughout the entire process of producing and publishing research outputs.

Data Manager Meetings

These six-monthly meetings provide:

- Education through expert guest speakers in areas relevant to data entry.
- Opportunity for site research staff to discuss issues arising, share expertise, and clarify definitions to enhance data quality.
- Feedback to sites on common errors, and tips to improve data collection processes.



ANZ MRDR Data Manager Meetings, April and October, 2025


Research support for investigators

The MRDR works with researchers to provide advice and support with:

- Feasibility of your proposal
- Research design and methodology
- Data analysis and interpretation
- Ethics and governance advice for your project.

Presentations at key national & international meetings

The MRDR has a strong presence at key national and international meetings, and its data are highly sought after for local collaborations and a growing number of international partnerships (see page 10).



L to R: Ghassan Zammar (ASH); Adam Irving and Jessica Ling (Blood)

MRDR Annual Open Breakfast Meeting at Blood

This annual open meeting brings together site staff, investigators, researchers, industry partners, patient support and advocacy groups, and government representatives to:

- Learn about the latest MRDR data and research developments
- Attend the first public presentations of recent registry analyses
- Network within the ANZ Myeloma research community.



Top: Networking pre-meeting. Bottom L to R: Andrew Spencer; Some MRDR Team members with Brad Augustson and Mark Henderson (CEO, Myeloma Australia); Brad Augustson (Meeting Chair)

MRDR SITES AND PRINCIPAL INVESTIGATORS

Ashford Cancer Centre: Stanley Cheung
Alfred Hospital: Andrew Spencer
Auckland Hospital: Nicole Chien
Austin Hospital: Jay Hocking
Bairnsdale Regional Health Service: Amanda Ormerod
Ballarat Hospital: Swe Htet
Border Medical and Oncology: Anish Puliyyail
Box Hill Hospital: Yee-Shuen Chong
Cabrini Hospital: Gaurav Srivastava
Calvary Mater Newcastle: Wojt Janowski
Canberra Hospital: Maansi Joshi (Acting)
Central Coast Haematology: Cecily Forsyth
Christchurch Hospital: Emma-Jane McDonald
Concord Hospital: Nicole Wong Doo
Cooks Hill Private Practice: Wojt Janowski
Dunedin Hospital: Ian Morison
Epworth Freemasons Hospital: Miles Prince
Fiona Stanley Hospital: Stephanie Lam
Flinders Medical Centre: TBC
Frankston Hospital: Patricia Walker
Geelong Hospital: Philip Campbell
Griffith Hospital: Georgia McCaughan
Hollywood Private Hospital: Bradley Augustson
ICON Cancer Care: Ian Irving
Latrobe Regional Hospital: Tricia Wright
Launceston General Hospital: Jessica Heenan
Lismore Hospital: Louise Imlay
Liverpool Hospital: Adam Bryant
Lyell McEwin Hospital: Stanley Cheung
Middlemore Hospital: Rajeev Rajagopal
Monash Medical Centre: Michael Low
Nelson Hospital: Luke Merriman
Nepean Cancer Centre: Anita Shetty
Northern Hospital: Rachel Cooke
North Shore Hospital: Anna Elinder-Camburn

Orange Health Service: Charmaine Wong
Palmerston North Hospital: Bart Baker
Peter Mac / Royal Melbourne: Amit Khot
Prince of Wales Hospital: Annmarie Bosco
Princess Alexandra Hospital: Peter Mollee
Royal Adelaide Hospital: Noemi Horvath
Royal Brisbane & Women's Hospital: Nicholas Weber
Royal Darwin Hospital: Tina Noutsos
Royal Hobart Hospital: Sonali Sadawarte
Royal North Shore Hospital: Ian Kerridge
Royal Prince Alfred Hospital: P Joy Ho
Sale: Central Gippsland Health: Amanda Ormerod
Sir Charles Gairdner Hospital: Bradley Augustson
St George Hospital: Sundra Ramanathan
St Vincent's Hospital, Melbourne: Hang Quach
St Vincent's Hospital, Sydney: Georgia McCaughan
Sunshine Hospital: William Renwick
Sunshine Coast University Hospital: Anthony Powell
Tamworth Hospital: Israfil Baluwala
Tauranga Hospital: Marie Hughes
Toowoomba Hospital: Philip Wong
Townsville Hospital: Andrew Birchley
Wagga Wagga Hospital: Georgia McCaughan
Wellington Hospital: Anup George
Western Cancer Centre, Dubbo: Thomas Gleeson
Whangarei Hospital: Sarah Poplar

MRDR STUDENTS

Sueh-li Lim:
Monash University, PhD completion 2025

Krystal Bergin:
Monash University, PhD completion 2022

Amanda Su:
University of Melbourne, Master of Epidemiology,
Research Project 2022

Daphne Antonopoulos:
University of Melbourne, Master of Cancer Sciences,
Research Project 2021

Rosalyn Cao:
Monash University, Master of Public Health,
Research Project 2019

Natthida Khajornjiraphan:
Monash University, Master of Clinical Research
Methods, Research Project 2019

Dervla O'Regan:
Monash University, Master of Clinical Pharmacy,
Research Project 2018

THANK YOU

The MRDR thanks participating individuals and sites, and our steering committee for all their work and contribution.

MRDR Steering Committee

- Prof Andrew Spencer:**
Alfred Hospital / Monash University VIC
- Dr Bradley Augustson:**
Sir Charles Gairdner Hospital WA
- Dr Krystal Bergin:**
Alfred Hospital VIC
- Prof Simon Harrison:**
Peter Mac / Royal Melbourne VIC
- Prof P Joy Ho:**
Royal Prince Alfred Hospital NSW
- A/Prof Tracy King:**
Royal Prince Alfred Hospital NSW
- Prof Zoe McQuilten:**
Alfred Hospital / Monash University VIC
- A/Prof Peter Mollee:**
Princess Alexandra Hospital QLD
- Prof Hang Quach:**
St Vincent's Hospital, Melbourne VIC
- Dr Rajeev Rajagopal:**
Middlemore Hospital, Auckland NZ
- Mr Brian Rosengarten:**
Myeloma Australia
- Prof Erica Wood:**
Monash University VIC

Thank you to the following MRDR industry funding partners. We appreciate your support and look forward to a very productive 2026.

abbvie

AMGEN

ANTGENE

Bristol Myers Squibb™

Celgene

GILEAD

GSK

Janssen
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

NOVARTIS

Pfizer

sanofi

Takeda

MRDR Management Committee

Coordinating Principal Investigator:
Prof Andrew Spencer

Head of Transfusion
Research Unit (TRU):
Prof Erica Wood

Associate Investigator:
Prof Zoe McQuilten

Research Fellow / ANZ MRDR
Project Manager:
Dr Elizabeth Moore

Data Manager:
Dr Cameron Wellard

ANZ & APAC MRDR
Research Officer:
Dr Tracy Zhang

TRU Deputy Director – Operations:
Mr Neil Waters

APAC MRDR Project Manager:
Ms Naomi Aoki

TRU Registries Project Manager:
Ms Vanessa Fox

Senior Data Officer:
Dr Yayehirad Melsew

Business Development Project
Manager (AMaRC):
Mr Khoa Le





MONASH
University

**CONTACT THE MYELOMA AND
RELATED DISEASES REGISTRY (MRDR)**

myeloma@monash.edu

1800 811 326

mrdr.net.au

